Aldeyra Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>AT</div>
ALDX -- USA Stock  

USD 11.71  0.38  3.14%

While some baby boomers are getting worried about healthcare space, it is reasonable to break down Aldeyra Therapeutics. We will evaluate why we are still confident in anticipation of a recovery. Is Aldeyra Therapeutics current valuation justified? We will cover the entity valuation to give you a better outlook on taking a position in the stock.
Published over two weeks ago
View all stories for Aldeyra Therapeutics | View All Stories
Breaking down Aldeyra Therapeutics real value
Aldeyra Therapeutics currently holds 15.01 M in liabilities with Debt to Equity (D/E) ratio of 0.22, which may suggest the firm is not taking enough advantage from borrowing. On a scale of 0 to 100, Aldeyra Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of -0.4057, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Aldeyra's beta means in this case. As returns on the market increase, returns on owning Aldeyra Therapeutics are expected to decrease at a much lower rate. During the bear market, Aldeyra Therapeutics is likely to outperform the market. Although it is vital to follow Aldeyra Therapeutics historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy in foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Aldeyra Therapeutics, which you can use to evaluate the performance of the firm. Please makes use of Aldeyra Therapeutics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to make a quick decision on whether Aldeyra Therapeutics price patterns will revert.
We determine the current worth of Aldeyra Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Aldeyra Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Aldeyra Therapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Aldeyra Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aldeyra Therapeutics. We calculate exposure to Aldeyra Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Aldeyra Therapeutics's related companies.

Aldeyra Therapeutics Investment Alerts

Aldeyra investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Aldeyra Therapeutics performance across your portfolios.Please check all investment alerts for Aldeyra

Aldeyra Therapeutics Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Aldeyra value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aldeyra Therapeutics competition to find correlations between indicators driving the intrinsic value of Aldeyra.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Aldeyra Therapeutics, but it might be worth checking our own buy vs. sell analysis

Purchase by Perceptive Advisors Llc of 50000 shares of Aldeyra Therapeutics

Legal trades by Aldeyra Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Aldeyra insider trading alert for perchase of common stock by Perceptive Advisors Llc, the corporate stakeholder, on 11th of January 2021. This event was filed by Aldeyra Therapeutics Inc with SEC on 2021-01-11. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Details

Net Loss for the year was (39.42 M) with profit before overhead, payroll, taxes, and interest of 0.

Aldeyra Therapeutics Earnings before Tax is decreasing over the last 8 years. The previous year's value of Aldeyra Therapeutics Earnings before Tax was -57,394,785. Further, Aldeyra Therapeutics Average Assets is increasing over the last 8 years. The previous year's value of Aldeyra Therapeutics Average Assets was 97,689,346.

Are Aldeyra Therapeutics technical ratios showing a relapse?

Aldeyra Therapeutics current downside deviation rises over 3.58. Aldeyra Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Aldeyra Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Aldeyra Therapeutics future alpha.

Our Bottom Line On Aldeyra Therapeutics

While some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Aldeyra Therapeutics may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take up new shares of Aldeyra nor trade your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aldeyra Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Aldeyra Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com